Share Name Share Symbol Market Type Share ISIN Share Description
Glaxosmithkline Plc LSE:GSK London Ordinary Share GB0009252882 ORD 25P
  Price Change % Change Share Price Shares Traded Last Trade
  58.80 4.56% 1,348.40 23,043,113 16:35:28
Bid Price Offer Price High Price Low Price Open Price
1,352.80 1,353.60 1,388.40 1,269.20 1,285.60
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 33,754.00 6,221.00 93.90 14.4 67,839
Last Trade Time Trade Type Trade Size Trade Price Currency
18:28:31 O 596 1,349.234 GBX

Glaxosmithkline (GSK) Latest News (20)

More Glaxosmithkline News
Glaxosmithkline Investors    Glaxosmithkline Takeover Rumours
Smart Money!
GSK is a large holding in the following funds:
 Fund  Percentage of Fund  Last Updated 
 BMO UK HIGH INCOME TRUST PLC 5.01% 2021-02-28

Glaxosmithkline (GSK) Discussions and Chat

Glaxosmithkline Forums and Chat

Date Time Title Posts
16/4/202100:59Glaxosmithkline - The recovery25,879
22/2/202112:31GlazoSmithKline - News & Information43
23/1/202114:27In Rude Health!1
06/10/202016:28covid vaccines not needed.. Trump. Calls experimental drugs "miracles from god"2

Add a New Thread

Glaxosmithkline (GSK) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
2021-04-15 16:23:351,321.1182010,833.09O
2021-04-15 16:18:141,348.40891,200.08O
2021-04-15 16:10:561,360.156528,868.18O
2021-04-15 16:10:051,356.844,42960,094.49O
2021-04-15 16:09:391,348.401,92025,889.28O
View all Glaxosmithkline trades in real-time

Glaxosmithkline (GSK) Top Chat Posts

Glaxosmithkline Daily Update: Glaxosmithkline Plc is listed in the Pharmaceuticals & Biotechnology sector of the London Stock Exchange with ticker GSK. The last closing price for Glaxosmithkline was 1,289.60p.
Glaxosmithkline Plc has a 4 week average price of 1,269.20p and a 12 week average price of 1,190.80p.
The 1 year high share price is 1,742.40p while the 1 year low share price is currently 1,190.80p.
There are currently 5,031,076,193 shares in issue and the average daily traded volume is 7,629,326 shares. The market capitalisation of Glaxosmithkline Plc is £67,839,031,386.41.
kev0856153: If you believe the brokers then selling GSK to buy AZN is a no-brainer trade. Last 2 broker notes for AZN and GSK AZN (current share price = 7227p) 08-Apr-21 Citigroup Buy price target 10,000.00p 08-Apr-21 Deutsche Buy price target 10,200.00p GSK (current share price = 1300p) 12-Apr-21 JPMorganCazenove Neutral price target 1,320.00p 08-Apr-21 Deutsche Sell price target 1,321.60p
poikka: It's all about mRNA, innit. This, as a reminder, from July 2020. "GlaxoSmithKline plc (LSE/NYSE: GSK) and CureVac today announced the signing of a strategic collaboration agreement for the research, development, manufacturing and commercialisation of up to five mRNA-based vaccines and monoclonal antibodies (mAbs) targeting infectious disease pathogens. The collaboration complements GSK’s existing mRNA capabilities with CureVac’s integrated mRNA platform. mRNA (messenger RNA) technology is a rapidly progressing, cutting-edge platform for the development of new vaccines and medicines, potentially expanding the range of diseases which can be prevented or treated, while also promising to significantly speed up development and manufacturing. mRNA enables protein synthesis in the human body, carrying the genetic code required for cells to manufacture and express proteins. By using mRNA technology in vaccines and medicines, specific proteins, or antigens, can be produced by the body’s own cells, enabling the human immune system to prevent or fight disease. CureVac’s leadership in mRNA technology, along with its mRNA manufacturing capability, complements GSK's existing scientific leadership in vaccines, including GSK's own self-amplifying mRNA (SAM) vaccine technology platform, and further builds on GSK's growing capability in mAbs innovation, aligned to its R&D focus on the science of immunology. Advancing mRNA-based vaccine and treatment technologies is also expected to play a role in further improving response against future pandemics. Roger Connor, President GSK Vaccines, said: “GSK’s self-amplifying mRNA (SAM) vaccine technology has shown us the potential of mRNA technology to advance the science of vaccine development, and CureVac’s experience complements our own expertise. Through the application of mRNA technology, including SAM, we hope to be able to develop and scale up advanced vaccines and therapies to treat and prevent infectious diseases quicker than ever before.” Dr. Franz-Werner Haas, acting Chief Executive Officer of CureVac, added: “We are delighted to partner with GSK. With this collaboration, we are gaining a world-class partner whose expertise and global footprint will allow us to further develop and translate the value of our platform into potential products for the world.”
poikka: Dated 29th March 2021. Up yours, VDL. "Issued: London, UK, Gaithersburg, MD GSK to support manufacture of up to 60 million doses of Novavax’ COVID-19 vaccine Manufacturing to take place at GSK UK facility at Barnard Castle GSK has reached an agreement in principle with Novavax and the UK Government Vaccines Taskforce to support manufacturing of up to 60 million doses of Novavax’ COVID-19 vaccine candidate (NVX-CoV2373) for use in the UK. GSK will provide ‘fill and finish’ manufacturing capacity at its Barnard Castle facility in the North East of England beginning as early as May 2021, with a rapid technology transfer between the two companies beginning immediately. The parties will negotiate a final agreement to include additional terms and conditions. The UK Government has secured 60 million doses of the vaccine under an advance purchase agreement with Novavax. The protein antigen component of NVX-CoV2373 is also produced in the North East of England by Novavax’ manufacturing partner, FUJIFILM Diosynth Biotechnologies, at their site in Billingham, Stockton-on-Tees. Fill and finish, to be provided by GSK, is the completion stage of vaccine manufacturing, preparing vials of the final vaccine and packaging them for distribution and use. The GSK site at Barnard Castle, which will deliver the vaccine doses under this collaboration, is a specialised facility in GSK’s global manufacturing network, which supports production of GSK pharmaceutical and vaccine products.
supermarky: gsk share price approaching recent resistance area.
tradermichael: The game changer will be when a combined vaccine is rapidly developed and manufactured (to routinely include all variants of concern), and also when there is an oral form of vaccine (essential for the sceptics and the 'third' world populations). I believe GSK and partners are targeting such approaches. In the meantime, its not unreasonable o expect the GSK share price to be underpinned.
spud: Glaxo’s vanishing trick When it splits into two, Glaxo will be takeover fodder. Management has come clean that the dividend must be cut. Holding shares in GlaxoSmithKline (GSK) must be the investment equivalent of waiting for a distant relative to die. You know there is a legacy in the offing, but you seriously wonder whether it will be worth the wait. Any legacy Glaxo offers will be turned into cash after it finally splits itself into two, sometime next year. After that, it is just a matter of time before a once-great company dies as one or both of its component parts are gobbled up by rivals or by private equity. When it comes, it will be a sad end to one of the greatest growth companies that British industry has seen in the past 50 years. For a short while in the 1980s Glaxo turned itself into the UK’s most valuable company and the world’s most valuable pharmaceuticals stock. Its success was almost exclusively based on Zantac, an ulcer treatment that was rejected by Glaxo’s rivals but became the world’s top-selling prescription drug. After Zantac lost its patent, Glaxo lost its edge. Nothing that Glaxo’s laboratories or its bosses did could make good Zantac’s declining revenues. Not that they were short of effort. During the 1990s, its bosses focused on growth by acquisition. In the process, the group turned itself into Glaxo Wellcome, then – in 2001 – came the deal that created the current corporate body. Along with SmithKline (which, ironically, had rejected Zantac) came the chief executive of the enlarged group, Jean-Pierre Garnier. He spent the next seven years presiding over much corporate activity and a share price response that said pretty clearly what investors thought about it (see Table 1). Table 1: How Glaxo's bosses have performed Jean-Pierre Garnier Andrew Witty Emma Walmsley Date appointed Jan-01 May-08 Apr-17 Share price (p) 1,905 1,121 1,660 FTSE All-Share 2,868 3,100 3,990 Date departed Apr-08 Mar-17 na Share price (p) 1,066 1,660 1,267 FTSE All-Share 2,927 3,953 3,726 Relative change (%) -45 16 -18 Absolute change (%) -44 48 -24 Source: FactSet Where corporate tinkering failed, Garnier’s successor, Sir Andrew Witty, turned to financial engineering to give the impression of growth. During his tenure, Glaxo’s net debt more than doubled from £6bn to over £13bn. Every bit of that £7bn-plus and another £2bn besides was spent buying in shares. The result was that operating profits shrank; earnings per share also shrank (although they would have shrunk even more without the buy-ins) and dividends rose a bit. Still, compared with the share price performance during Garnier’s tenure, Witty’s time in charge could be judged a success. The same might be said of his time versus that of his successor, Emma Walmsley. Where Witty employed financial engineering, the current boss is turning to another old faithful in the handbook of corporate legerdemain – splitting the business into two. This relies on the idiosyncratic logic of corporate finance that, when a company is valued, one often equals less than one, but two halves, when added together, must always equal more than one. Thus Glaxo’s consumer healthcare side – 22 per cent of underlying group operating profits in 2020 – is being split from the conventional pharmaceuticals side. This will be the culmination of Walmsley’s efforts, which have focused on the consumer operation (star products, Sensodyne toothpaste, Eno liver salts, Voltaren pain killer). First, healthcare was augmented via a deal with Novartis (SWX:NOV). Then the minority stake in the division held by US rival Pfizer (US:PFE) was bought out. Now, as a wholly-owned and pumped-up division, it is ready for independence. However, when Glaxo’s two sides eventually split and each gets its own London-market listing, the move will chiefly highlight what Table 2 makes clear anyway – that, in the global scheme of things, Glaxo is already an also-ran. The table ranks nine pharma groups by their stock market valuation. Glaxo comes in ninth. Table 2: How Glaxo compares Company Share price* Mkt Cap (£bn) Sales (£m) Op profit (£m) Profit margin (%) Return on assets (%) Net debt/Ebitda R&D/Sales (%) Price/sales PE ratio† Johnson & Johnson 164.92 315.4 64,400 15,529 24.1 9.0 na 12.7 5.2 17.6 Roche Holding 308.30 216.5 48,456 13,728 30.4 16.9 0.1 18.2 4.4 14.9 Novartis 81.72 162.6 37,945 8,437 22.2 6.5 1.4 18.1 4.2 14.8 Pfizer 34.82 141.4 32,681 6,831 20.9 4.0 na 19.5 4.3 12.6 Merck & Co 75.04 139.7 37,426 9,702 25.9 8.1 na 19.5 4.4 13.0 Bristol-Myers Squibb 60.23 100.3 33,156 3,490 10.5 -7.1 na 13.8 3.6 8.3 AstraZeneca 72.89 95.5 19,114 2,200 11.5 4.1 2.1 21.1 4.9 23.7 Sanofi 80.77 88.3 32,039 7,777 24.3 10.8 na 15.2 2.7 12.5 GlaxoSmithKline 12.70 63.7 34,099 7,373 21.6 7.2 2.6 11.8 2.0 11.7 Source: FactSet; * local currency; † Next 12 mnths earnings As such, it is already easy for a pharma giant, in combination with its Wall Street piranhas, to rip it apart. By splitting the group, which will divide its market value roughly into three-quarters for pharmaceuticals, one-quarter for healthcare, Glaxo is turning itself into bite-sized morsels. For example, roughly speaking, to buy the healthcare side would cost Johnson & Johnson (US:JNJ) 5 per cent of its current market value. This much is pretty obvious, but the question is whether Glaxo’s shareholders should stick around for any payday or, indeed, whether the stock should be bought as takeover fodder. This is especially pertinent for income investors because Glaxo’s bosses have finally come clean that the dividend – 80p a year for seven years now – will have to be cut and Glaxo’s shares without the dividend yield won’t be the same, to put it mildly. Shareholders have every reason to be miffed. After all, one justification for splitting the group was that the dividend would be saved. Maintaining the payout was a factor behind the share price recovery that started in early 2018 and it was almost promised in the gushing PR blurb that accompanied the tie-up with Pfizer. Now, there is guff about “optimised capital structure” and “delivering sustainable long-term shareholder value” – that’s good coming from Glaxo – but the long and the short of it is that the dividend will be cut. At least its bosses promise another 80p for 2021. The intuitive response might be to tell Glaxo to stick it, but that would be silly. After all, with the share price down to £12.70, the dividend yields 6.3 per cent. Which leaves holding Glaxo’s shares feeling a bit like having herpes – easier to acquire than to be rid of, even though Glaxo does have a vaccine – but I am itching to be rid of them. spud
essentialinvestor: Many of the major pharma companies sell on multiples of approx 13.5-15.5x earnings. That's based on FY 2021 sector estimates. Merck sells on approx 13.5 x forward earnings, has significantly lower net debt than GSK, eventhough it is materially more profitable. With hindsight, the GSK price circa £18 looks like a gift and arguably also considerably overvalued the business. LLY and AZN command higher ratings as future earnings growth is estimated well ahead of average - obviously that growth needs to be delivered on. The picture changes for GSK if they can reignite growth in core pharma Their vaccine outlook appears strong( post pandemic) CH spin off should create value, the ViiV jv is highly successful. A lot depends on whether the very big bet on oncology delivers and a couple of recent pipeline failures look to be weighing on the share price
supermarky: If 1200 sticks and acts as a floor i am very happy. If gsk drops further even to say 1000 i am happy as I will add many more. Just my little strategy. One can think of the permutations and procrastinate until the cows come home. At some point a decision needs to be made. Nobody is ringing the bell today to say this is the support and if you buy now you will be the best stock trader ever as you got in at the bottom. GSK share price and sentiment has obviously taken one hell of a beating but looking ahead sentiment can change quickly.
2liveinhope: I was just about to buy today, thinking a rising share price was a good thing, locking in a 12 gbp share price bottom. Trying to average down not having been too clever previous. Then I started thinking,stronger USD higher GSK share price today. Lower USD lower GSK share price? What will the 1.9 trillion USD stimulus wanted by the democratic by mid March 21 do to the USD value and in turn the GSK share price?And no news from GSK due regarding dividends and splits until June. Is this going lower and today is just a pause or is today just a good excuse for traders to make 12 the bottom?
unastubbs: GlaxoSmithKline: Distribution Change Signals A Future Of Acquisitions Feb. 15, 2021 5:36 AM ETGlaxoSmithKline plc (GSK)43 Comments22 Likes Summary GSK is one of the few discounted pharma stocks which also provides an ample dividend. Unfortunately, recent announcements have signaled to the markets that the dividend will probably be reduced in order to charge growth projects. The pull-out from oncology some years ago may have cost it a large market share, but we believe the GSK pipeline looked good enough for satisfying a dividend-oriented shareholder base. This shift in direction will likely lead to an acquisition-heavy future. With a future of consolidation, GSK will probably overpay for growth, and thus we are no longer bullish on the stock. We don't like inorganic growth, and no one really should especially in a high multiple market like this one. With GlaxoSmithKline's (NYSE:GSK) recent announcement that it will be revising its dividend policy due to what is being perceived by investors as a low-productivity R&D house, inorganic growth is a likely future for the company. In addition to the fact that GSK's dividend will be cut, and despite the fact that the spin-off of its consumer healthcare division will do good for the balance sheet, we don't really see any good reason to expect any meaningful gains over the medium term, as fewer catalysts and a reduced dividend will ward interest away. While we remain confident in the stability and health of the business as is, and indeed of its debt capacity, mainly thanks to a deferred set of patent expirations towards the end of the decade, we are not going to see our money erode from value-destroying acquisitions and thus have left our investment. The Distribution Policy Announcement The distribution policy announcement was a bit of a surprise to us, although several equity research houses were indicating that it would occur, likely thanks to their discussions with management. While some analysts suspected that the stock would suffer due to CDC guidelines suggesting some time lag between vaccines of any kind after the Pfizer (NYSE:PFE) COVID-19 vaccine is administered, we thought that this risk to performance was overdone and not sufficient reason to de-rate the stock. Indeed, even by CDC guidelines advising a 15-day lag and due to the slow rollout of the vaccine in several geographies, the deferral impact on vaccine schedules for GSK would have been relatively small. What GSK is suffering from now with its 8% slide from previously stable levels, and what the distribution policy announcement indicates, is that GSK has been suffering primarily from a sentiment problem. With Pfizer's spinoff of Viatris (NASDAQ:VTRS) and other similar moves by companies to accentuate their biopharma businesses, GSK was under a similar pressure. Indeed, this pressure has compounded on the predecessor CEO's mistake of not chasing the oncology market, which at the time was ripe for the taking. The corporate restructuring around the consumer health business was the beginnings of responding to that pressure, as it could emphasize further GSK's more innovative businesses. While this was a reasonable move in our view, also for the debt relief that carving out a stable vehicle like that would provide, this further move is not. With a relatively forgiving patent expiration timeline, the worst has for the most part passed for GSK. While some patent expirations will occur in coming years in its vaccine portfolio, which we still believe is an underappreciated jewel across the pharma landscape, there are also promising growth trajectories on several GSK products, with a reasonable set of read-outs coming up soon for promising drugs. By no means is GSK a Regeneron (NASDAQ:REGN), but as it stood it was a solid company with growth opportunities to hedge declines in its generics portfolio. We are not yield chasers, but the decision to reverse the payout policy seems to be a situation where management is going to want to ready the kegs to fire off on acquisitions to frontload growth and the perception of innovation before shareholders become too unhappy. Tough Acquisition Environment Inorganic growth is not what you want in your portfolio. While in selective niches it can be attractive, like for example in pharma royalties, a PE-esque landscape dominated by Royalty Pharma (NASDAQ:RPRX), multiples are generally very high, especially in hardcore biotech where Redditors have recently taken their money. It is unlikely that GSK will be rolling up very early-stage pharma companies, but it will very likely be making acquisitions to bolster the currently marginal oncology franchise, as well as companies that will provide patents to further pursue inflammation and respiratory. Multiples across later-stage biotech are becoming more and more dear, especially in the small-cap and mid-cap space where GSK has and will be wading. It relies very heavily on execution by the acquiring companies. We've seen this with Bristol-Myers' (NYSE:BMY) move into Myokardia, where we detailed carefully the implications on LT shareholder value for BMY. Just look at the Biotech ETF (NASDAQ:IBB) to understand the issue. Conclusions If GSK is indeed preparing for an inorganic growth spell, and if these transactions don't work out for it, and they might not, the sting to shareholder will be keen, as a languishing R&D picture for the medium term in the context of a botched acquisition will look remarkably bad. We still think that there is a fair bit to offer in the GSK pipeline, and current growers in the portfolio, incidentally from previous and very successful acquisitions by GSK, have room to offset the generics erosion and establish themselves as important contributors to the mix. The pipeline looks alright as well, although definitely not outstanding. Moreover, the efforts with the consumer healthcare JV are also likely to pay off by reducing confounders in the GSK picture. However, this decision to reverse on the payout policy, which GSK stood by just a quarter or two ago through the worst of the COVID-19 lockdowns, reeks a little of management desperation. We don't believe the desperation to be founded; however, we don't want our investment piloted by short-term agendas when growth could have been reasonably expected just over the horizon. hTTps://
Glaxosmithkline share price data is direct from the London Stock Exchange
ADVFN Advertorial
Your Recent History
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20210416 00:08:42